急性虚血性脳卒中（AIS）市場 - 競合情勢

急性虚血性脳卒中（AIS）は、対象16カ国において2023年に90,000,000例以上が有病者と診断されると予測されています。AISの治療薬として市販されているのは8品目のみで、アルテプラーゼはさまざまな企業がさまざまなブランド名で複数の地域で販売しています。AISのパイプラインは非常に強固で、1剤が登録前段階にあり、13剤が現在第III相の開発段階にあります。

過去10年間で、AISを対象とした臨床試験は合計662件実施されました。試験数が最も多かったのは2021年の100試験で、次いで2022年の92試験でした。AIS資産の開発において、南米とアフリカではライセンス契約が支配的な取引形態として浮上しました。買収とパートナーシップは、欧州、アジア太平洋、北米の市場で優勢でした。

当レポートでは、世界の急性虚血性脳卒中（AIS）市場について調査し、疾患の概要とともに、治験動向、パイプライン概要、将来の見通しなどを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 病気の情勢

• 病気の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤の評価

• 主要な上市済み薬剤
• 作用機序別概要
• 投与経路別概要
• 上市済み薬剤のプロファイルと売上予測

第5章 薬価設定と償還の評価

• 年間治療費
• 薬価設定と償還期間

第6章 パイプライン薬剤の評価

• 第Ⅲ相パイプライン薬剤
• 開発段階別概要
• 分子タイプ別概要
• 作用機序別概要
• 投与経路別概要
• 医薬品特異的相転移成功率（PTSR）と承認の可能性（LoA）
• 治療領域および適応症固有のPTSRおよびLoA

第7章 臨床試験の評価

• 歴史的概要
• 相別概要
• ステータス別概要
• 進行中および計画中の試験の相別概要
• 仮想コンポーネントを使用した治験
• 地理的概要
• 地域別の単一国および多国籍試験
• 上位20のスポンサーと相別内訳
• 上位20のスポンサーのステータス別内訳
• エンドポイントステータス別概要
• 人種および民族別の概要
• 登録データ
• 治験サイトの上位20か国
• 世界の上位20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in AIS therapeutics.

• More than 90,000,000 diagnosed prevalent cases of AIS are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for AIS.
• There are only eight marketed drugs for AIS, with alteplase being marketed by various companies under various brand names and in multiple geographies.
• The pipeline for AIS is very robust with one drug in pre-registration stage, whereas 13 drugs are currently in Phase III development stage.
• Over the past 10 years, a total of 662 trials have been conducted for AIS. The highest number of trials occurred in 2021, with 100 trials, followed by 2022 with 92 trials.
• In the development of AIS assets, licensing agreements emerged as the dominant deal type in South America and Africa. Acquisitions and partnership displayed prevalence in the markets of Europe, Asia-Pacific, and North America.

Scope

GlobalData's AIS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the AIS market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AIS market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer